齐鲁晚报.齐鲁壹点通讯员曹婷婷 2月8日，鲁南制药集团与中国工程院刘良院士举行座谈交流会。中国工程院院士、广州中医药大学终身教授刘良，鲁南制药集团党委书记、董事长、总经 理张贵民出席会议。 会上，刘良院士首先对鲁南制药集团在中医药研发与质量坚守方面取得的成就表示赞赏。他指出，中医药是具有完整理论体系和实践价值的生命科学，其 背后蕴藏着深刻的物质基础与作用机理。他强调，中医药的研究应当坚持"宏观与微观并重"，既尊重传统整体观、辨证观，也积极运用现代科技手段揭示 其科学内涵。他提出了四点战略性建议(布局独家原创药、加强智能化建设、参与ISO国际标准研制、探索时间治疗学研究)，为鲁南制药集团未来发展指 明了重要方向。 张贵民以《生命的中医药思考》为题展开论述，结合鲁南制药集团的实践探索，系统阐述了中医药的整体观与系统论。他以荆防颗粒(启达力)为实例，阐 明该药不仅广泛应用于感冒防治，更在免疫平衡调控、慢性病系统管理等层面展现出多重潜力，凸显了中医药的独特优势。他表示，鲁南制药集团在传承 经典名方的基础上，运用现代科技手段深入挖掘中药的核心价值，力求实现传统医学与现代科学的有机融合，争取为推动中医药事业的传承创新和高 ...

Financial Performance - Yisheng Pharmaceutical (002566) reported a net profit decline of 43.71% year-on-year for the first half of 2025, with total revenue of 328 million yuan, down 5.75% from the previous year [1] - The gross profit margin decreased to 75.15%, a drop of 2.02% year-on-year, while the net profit margin fell to 6.05%, down 36.94% [1] - The company’s total expenses (selling, administrative, and financial) reached 219 million yuan, accounting for 66.83% of revenue, an increase of 2.16% year-on-year [1] Cash Flow and Financial Ratios - The company experienced a significant increase in financial expenses by 502.37% due to reduced interest income [3] - The net cash flow from investment activities increased by 100.86%, attributed to higher cash recovered from investments compared to the previous year [3] - The company’s return on invested capital (ROIC) was reported at 2.08%, indicating historically weak capital returns [3] Accounts Receivable and Inventory - The accounts receivable to profit ratio reached 312.96%, suggesting potential issues with cash collection [4] - The inventory to revenue ratio stood at 241.32%, indicating a high level of inventory relative to sales [4] Strategic Focus - The company plans to increase its research and development efforts to meet market demands, addressing concerns about the lack of new product development in traditional Chinese medicine [5]